Cargando…
The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113
In the FUGA-BT trial (JCOG1113), gemcitabine plus S-1 (GS) showed non-inferiority to gemcitabine plus cisplatin (GC) in overall survival (OS) with good tolerance for patients with advanced biliary tract cancer (BTC). We performed a subgroup analysis focused on the elderly cohort of this trial. All 3...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770671/ https://www.ncbi.nlm.nih.gov/pubmed/35046457 http://dx.doi.org/10.1038/s41598-021-04550-8 |
| _version_ | 1784635421129441280 |
|---|---|
| author | Yamada, Ikuhiro Morizane, Chigusa Okusaka, Takuji Mizusawa, Junki Kataoka, Tomoko Ueno, Makoto Ikeda, Masafumi Okano, Naohiro Todaka, Akiko Shimizu, Satoshi Mizuno, Nobumasa Sekimoto, Mitsugu Tobimatsu, Kazutoshi Yamaguchi, Hironori Nishina, Tomohiro Shirakawa, Hirofumi Kojima, Yasushi Oono, Takamasa Kawamoto, Yasuyuki Furukawa, Masayuki Iwai, Tomohisa Sudo, Kentaro Okamura, Keiya Yamashita, Tatsuya Kato, Naoya Shioji, Kazuhiko Shimizu, Kyouko Nakagohri, Toshio Kamata, Ken Ishii, Hiroshi Furuse, Junji |
| author_facet | Yamada, Ikuhiro Morizane, Chigusa Okusaka, Takuji Mizusawa, Junki Kataoka, Tomoko Ueno, Makoto Ikeda, Masafumi Okano, Naohiro Todaka, Akiko Shimizu, Satoshi Mizuno, Nobumasa Sekimoto, Mitsugu Tobimatsu, Kazutoshi Yamaguchi, Hironori Nishina, Tomohiro Shirakawa, Hirofumi Kojima, Yasushi Oono, Takamasa Kawamoto, Yasuyuki Furukawa, Masayuki Iwai, Tomohisa Sudo, Kentaro Okamura, Keiya Yamashita, Tatsuya Kato, Naoya Shioji, Kazuhiko Shimizu, Kyouko Nakagohri, Toshio Kamata, Ken Ishii, Hiroshi Furuse, Junji |
| author_sort | Yamada, Ikuhiro |
| collection | PubMed |
| description | In the FUGA-BT trial (JCOG1113), gemcitabine plus S-1 (GS) showed non-inferiority to gemcitabine plus cisplatin (GC) in overall survival (OS) with good tolerance for patients with advanced biliary tract cancer (BTC). We performed a subgroup analysis focused on the elderly cohort of this trial. All 354 enrolled patients in JCOG1113 were classify into two groups; < 75 (non-elderly) and ≥ 75 years (elderly) group. We investigated the influence of age on the safety analysis, including the incidence of chemotherapeutic adverse events and the efficacy analysis, including OS. There were no remarkable differences in OS between the elderly (n = 60) and the non-elderly groups (n = 294). In the elderly group, median OS was 12.7 and 17.7 months for those who received GC (n = 20) and GS (n = 40), respectively. The prevalence of all-grade adverse events was similar between the elderly and the non-elderly groups. However, among the elderly group, Grade ≥ 3 hematological adverse events were more frequently observed in the GC arm than in the GS arm. The clinical outcomes of combination chemotherapy in elderly patients with advanced BTC were comparable to non-elderly patients. GS may be the more favorable treatment for elderly patients with advanced BTC. |
| format | Online Article Text |
| id | pubmed-8770671 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87706712022-01-24 The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113 Yamada, Ikuhiro Morizane, Chigusa Okusaka, Takuji Mizusawa, Junki Kataoka, Tomoko Ueno, Makoto Ikeda, Masafumi Okano, Naohiro Todaka, Akiko Shimizu, Satoshi Mizuno, Nobumasa Sekimoto, Mitsugu Tobimatsu, Kazutoshi Yamaguchi, Hironori Nishina, Tomohiro Shirakawa, Hirofumi Kojima, Yasushi Oono, Takamasa Kawamoto, Yasuyuki Furukawa, Masayuki Iwai, Tomohisa Sudo, Kentaro Okamura, Keiya Yamashita, Tatsuya Kato, Naoya Shioji, Kazuhiko Shimizu, Kyouko Nakagohri, Toshio Kamata, Ken Ishii, Hiroshi Furuse, Junji Sci Rep Article In the FUGA-BT trial (JCOG1113), gemcitabine plus S-1 (GS) showed non-inferiority to gemcitabine plus cisplatin (GC) in overall survival (OS) with good tolerance for patients with advanced biliary tract cancer (BTC). We performed a subgroup analysis focused on the elderly cohort of this trial. All 354 enrolled patients in JCOG1113 were classify into two groups; < 75 (non-elderly) and ≥ 75 years (elderly) group. We investigated the influence of age on the safety analysis, including the incidence of chemotherapeutic adverse events and the efficacy analysis, including OS. There were no remarkable differences in OS between the elderly (n = 60) and the non-elderly groups (n = 294). In the elderly group, median OS was 12.7 and 17.7 months for those who received GC (n = 20) and GS (n = 40), respectively. The prevalence of all-grade adverse events was similar between the elderly and the non-elderly groups. However, among the elderly group, Grade ≥ 3 hematological adverse events were more frequently observed in the GC arm than in the GS arm. The clinical outcomes of combination chemotherapy in elderly patients with advanced BTC were comparable to non-elderly patients. GS may be the more favorable treatment for elderly patients with advanced BTC. Nature Publishing Group UK 2022-01-19 /pmc/articles/PMC8770671/ /pubmed/35046457 http://dx.doi.org/10.1038/s41598-021-04550-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Article Yamada, Ikuhiro Morizane, Chigusa Okusaka, Takuji Mizusawa, Junki Kataoka, Tomoko Ueno, Makoto Ikeda, Masafumi Okano, Naohiro Todaka, Akiko Shimizu, Satoshi Mizuno, Nobumasa Sekimoto, Mitsugu Tobimatsu, Kazutoshi Yamaguchi, Hironori Nishina, Tomohiro Shirakawa, Hirofumi Kojima, Yasushi Oono, Takamasa Kawamoto, Yasuyuki Furukawa, Masayuki Iwai, Tomohisa Sudo, Kentaro Okamura, Keiya Yamashita, Tatsuya Kato, Naoya Shioji, Kazuhiko Shimizu, Kyouko Nakagohri, Toshio Kamata, Ken Ishii, Hiroshi Furuse, Junji The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113 |
| title | The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113 |
| title_full | The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113 |
| title_fullStr | The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113 |
| title_full_unstemmed | The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113 |
| title_short | The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113 |
| title_sort | clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of jcog1113 |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770671/ https://www.ncbi.nlm.nih.gov/pubmed/35046457 http://dx.doi.org/10.1038/s41598-021-04550-8 |
| work_keys_str_mv | AT yamadaikuhiro theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT morizanechigusa theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT okusakatakuji theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT mizusawajunki theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT kataokatomoko theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT uenomakoto theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT ikedamasafumi theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT okanonaohiro theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT todakaakiko theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT shimizusatoshi theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT mizunonobumasa theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT sekimotomitsugu theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT tobimatsukazutoshi theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT yamaguchihironori theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT nishinatomohiro theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT shirakawahirofumi theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT kojimayasushi theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT oonotakamasa theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT kawamotoyasuyuki theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT furukawamasayuki theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT iwaitomohisa theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT sudokentaro theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT okamurakeiya theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT yamashitatatsuya theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT katonaoya theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT shiojikazuhiko theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT shimizukyouko theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT nakagohritoshio theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT kamataken theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT ishiihiroshi theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT furusejunji theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT theclinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT yamadaikuhiro clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT morizanechigusa clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT okusakatakuji clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT mizusawajunki clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT kataokatomoko clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT uenomakoto clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT ikedamasafumi clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT okanonaohiro clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT todakaakiko clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT shimizusatoshi clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT mizunonobumasa clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT sekimotomitsugu clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT tobimatsukazutoshi clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT yamaguchihironori clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT nishinatomohiro clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT shirakawahirofumi clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT kojimayasushi clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT oonotakamasa clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT kawamotoyasuyuki clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT furukawamasayuki clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT iwaitomohisa clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT sudokentaro clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT okamurakeiya clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT yamashitatatsuya clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT katonaoya clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT shiojikazuhiko clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT shimizukyouko clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT nakagohritoshio clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT kamataken clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT ishiihiroshi clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT furusejunji clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 AT clinicaloutcomesofcombinationchemotherapyinelderlypatientswithadvancedbiliarytractcanceranexploratoryanalysisofjcog1113 |